Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis

Autor: Kasia Owczarczyk, Matthew D. Cascino, Cecile Holweg, Gaik W. Tew, Ward Ortmann, Timothy Behrens, Thomas Schindler, Carol A. Langford, E. William St. Clair, Peter A. Merkel, Robert Spiera, Philip Seo, Cees G.M. Kallenberg, Ulrich Specks, Noha Lim, John Stone, Paul Brunetta, Marco Prunotto, the RAVE-ITN Research Group
Přispěvatelé: Translational Immunology Groningen (TRIGR)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Vasculitis
Male
medicine.medical_specialty
Microscopic Polyangiitis
Autoimmunity
Receptors
Fc
medicine.disease_cause
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Azathioprine
medicine
Humans
Clinical Trials
Cyclophosphamide
B cell
business.industry
Remission Induction
Granulomatosis with Polyangiitis
General Medicine
Middle Aged
medicine.disease
Antigens
CD20
Prognosis
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Rheumatoid arthritis
Case-Control Studies
Medicine
Biomarker (medicine)
Rituximab
Female
Clinical Medicine
Microscopic polyangiitis
business
Granulomatosis with polyangiitis
Biomarkers
medicine.drug
Follow-Up Studies
Zdroj: JCI Insight
JCI Insight, 5(18):e136180. AMER SOC CLINICAL INVESTIGATION INC
JCI Insight, Vol 5, Iss 18 (2020)
ISSN: 2379-3708
0010-4299
Popis: BACKGROUND Baseline expression of FCRL5, a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of FCRL5 as a potential biomarker of clinical response to RTX in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). METHODS A previously validated quantitative PCR–based (qPCR-based) platform was used to assess FCRL5 expression in patients with GPA/MPA (RAVE trial, NCT00104299). RESULTS Baseline FCRL5 expression was significantly higher in patients achieving complete remission (CR) at 6, 12, and 18 months, independent of other clinical and serological variables, among those randomized to RTX but not cyclophosphamide-azathioprine (CYC/AZA). Patients with baseline FCRL5 expression ≥ 0.01 expression units (termed FCRL5hi) exhibited significantly higher CR rates at 6, 12, and 18 months as compared with FCRL5lo subjects (84% versus 57% [P = 0.016], 68% versus 40% [P = 0.02], and 68% versus 29% [P = 0.0009], respectively). CONCLUSION Our data taken together suggest that FCRL5 is a biomarker of B cell lineage associated with increased achievement and maintenance of complete remission among patients treated with RTX and warrant further investigation in a prospective manner. FUNDING The analysis for this study was funded by Genentech Inc.
FcRL5 is a biomarker of B cell lineage associated with maintenance of complete remission among patients treated with rituximab in granulomatosis with polyangiitis and microscopic polyangiitis.
Databáze: OpenAIRE
Externí odkaz: